Contrasting 20/20 Biolabs (AIDX) and Its Peers

20/20 Biolabs (NASDAQ:AIDX – Get Free Report) is one of 233 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it contrast to its competitors? We will compare 20/20 Biolabs to related businesses based on the strength of its risk, dividends, earnings, profitability, analyst recommendations, valuation and institutional ownership.

Profitability

This table compares 20/20 Biolabs and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
20/20 Biolabs N/A N/A N/A
20/20 Biolabs Competitors -7.87% -135.89% -1.58%

Analyst Recommendations

This is a breakdown of current ratings for 20/20 Biolabs and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
20/20 Biolabs 1 0 1 0 2.00
20/20 Biolabs Competitors 1880 7755 13394 833 2.55

20/20 Biolabs presently has a consensus target price of $5.00, suggesting a potential upside of 2,517.80%. As a group, “Healthcare Providers & Services” companies have a potential upside of 12.79%. Given 20/20 Biolabs’ higher possible upside, analysts clearly believe 20/20 Biolabs is more favorable than its competitors.

Insider & Institutional Ownership

56.7% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 27.7% of 20/20 Biolabs shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Providers & Services” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares 20/20 Biolabs and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
20/20 Biolabs $2.05 million -$3.74 million -0.35
20/20 Biolabs Competitors $19.21 billion $301.67 million -1.66

20/20 Biolabs’ competitors have higher revenue and earnings than 20/20 Biolabs. 20/20 Biolabs is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

About 20/20 Biolabs

(Get Free Report)

20/20 BioLabs is a clinical laboratory company that has provided diagnostic testing services, with a focus on infectious diseases. Its offerings have included COVID-19 testing, such as molecular and antibody-based tests, along with related laboratory services. The company became known during the COVID-19 pandemic, when it supported demand for testing in the United States. Publicly available information about its broader operations and leadership is limited.

Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.